Patients with TSC2 mutations had significantly earlier angiomyolipoma detection (13 vs. 23 years) and showed significantly higher rates of multiple and bilateral angiomyolipomas than those with TSC1 mutations [6]. The gene discussed is TSC2; the disease is angiomyolipoma.